drugset / Trial / NCT00403494

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

NCT00403494

Phase 2 Completed 190 enrolled BioMarin Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).

Timeline

Start
2006-12
Primary completion
2008-11
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown 400 mg Oral